In summary, our results suggested that fruquintinib, a VEGFR1, 2, and 3 inhibitor, when administrated at a lower dose, could optimize the immunosuppressive TME and increase the therapeutic response to immunotherapy both in mice colon cancer models and in clinical colon cancer patients. Here, FLT1 is linked to malignant colon neoplasm.